BRPI0613970B8 - composição para o tratamento ou para a prevenção de câncer de cólon compreende uma quantidade farmaceuticamente eficaz de um sirna contra um polinucleotídeo de tom 34 - Google Patents

composição para o tratamento ou para a prevenção de câncer de cólon compreende uma quantidade farmaceuticamente eficaz de um sirna contra um polinucleotídeo de tom 34

Info

Publication number
BRPI0613970B8
BRPI0613970B8 BRPI0613970A BRPI0613970A BRPI0613970B8 BR PI0613970 B8 BRPI0613970 B8 BR PI0613970B8 BR PI0613970 A BRPI0613970 A BR PI0613970A BR PI0613970 A BRPI0613970 A BR PI0613970A BR PI0613970 B8 BRPI0613970 B8 BR PI0613970B8
Authority
BR
Brazil
Prior art keywords
colon cancer
treatment
polynucleotide
tone
prevention
Prior art date
Application number
BRPI0613970A
Other languages
English (en)
Portuguese (pt)
Inventor
Tahara Hideaki
Matsushima Satoshi
Tsunoda Takuya
Furukawa Yoichi
Nakamura Yusuke
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BRPI0613970A2 publication Critical patent/BRPI0613970A2/pt
Publication of BRPI0613970B1 publication Critical patent/BRPI0613970B1/pt
Publication of BRPI0613970B8 publication Critical patent/BRPI0613970B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0613970A 2005-07-27 2006-07-21 composição para o tratamento ou para a prevenção de câncer de cólon compreende uma quantidade farmaceuticamente eficaz de um sirna contra um polinucleotídeo de tom 34 BRPI0613970B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70326505P 2005-07-27 2005-07-27
US60/703,265 2005-07-27
PCT/JP2006/314947 WO2007013576A1 (en) 2005-07-27 2006-07-21 Colon cancer related gene tom34

Publications (3)

Publication Number Publication Date
BRPI0613970A2 BRPI0613970A2 (pt) 2011-02-22
BRPI0613970B1 BRPI0613970B1 (pt) 2019-10-29
BRPI0613970B8 true BRPI0613970B8 (pt) 2021-05-25

Family

ID=37499354

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0613970A BRPI0613970B8 (pt) 2005-07-27 2006-07-21 composição para o tratamento ou para a prevenção de câncer de cólon compreende uma quantidade farmaceuticamente eficaz de um sirna contra um polinucleotídeo de tom 34

Country Status (18)

Country Link
US (1) US8674059B2 (https=)
EP (1) EP1910839B1 (https=)
JP (2) JP5095603B2 (https=)
KR (2) KR101325194B1 (https=)
CN (1) CN101278196B (https=)
AU (1) AU2006273192B2 (https=)
BR (1) BRPI0613970B8 (https=)
CA (1) CA2616497C (https=)
CY (1) CY1117839T1 (https=)
DK (1) DK1910839T3 (https=)
ES (1) ES2584247T3 (https=)
HU (1) HUE027330T2 (https=)
PL (1) PL1910839T3 (https=)
PT (1) PT1910839T (https=)
RU (2) RU2449020C2 (https=)
SG (1) SG163614A1 (https=)
SI (1) SI1910839T1 (https=)
WO (1) WO2007013576A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102439147A (zh) * 2009-03-04 2012-05-02 肿瘤疗法科学股份有限公司 Vangl1肽及包含它们的疫苗
TWI485245B (zh) * 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
TW201211250A (en) * 2010-09-07 2012-03-16 Oncotherapy Science Inc VANGL1 peptides and vaccines including the same
SG190407A1 (en) * 2010-12-02 2013-06-28 Oncotherapy Science Inc Tomm34 peptides and vaccines including the same
KR102127211B1 (ko) 2011-10-28 2020-06-29 온코세라피 사이언스 가부시키가이샤 Ｔｏｐｋ 펩티드 및 이를 포함하는 백신
SG11201405578TA (en) 2012-03-09 2014-11-27 Oncotherapy Science Inc Pharmaceutical composition containing peptide
EP3187191B1 (en) * 2014-08-26 2020-04-08 NKMAX Co., Ltd. Antibody for recognizing specific motif of wls protein, and pharmaceutical composition containing same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
JPH04504416A (ja) * 1989-02-17 1992-08-06 コセルコ・ミモトープス・ピィ・ティ・ワイ．エル・ティ・ディ． ペプチドの使用方法と合成方法
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
EP0960204A4 (en) 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US7166573B1 (en) * 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
EP1250145A4 (en) 2000-01-03 2003-03-26 Argonex Pharmaceuticals Inc PEPTIDES DERIVED FROM ONCOGENE C-SKI FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF CANCER
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20040181344A1 (en) * 2002-01-29 2004-09-16 Massachusetts Institute Of Technology Systems and methods for providing diagnostic services
TW200413406A (en) 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
PT1581812E (pt) 2003-01-06 2008-09-22 Wyeth Corp Composições e métodos para diagnóstico e tratamento de cancros do cólon

Also Published As

Publication number Publication date
KR20080040738A (ko) 2008-05-08
JP5095603B2 (ja) 2012-12-12
KR20130087639A (ko) 2013-08-06
US8674059B2 (en) 2014-03-18
HK1115193A1 (zh) 2008-11-21
SG163614A1 (en) 2010-08-30
BRPI0613970B1 (pt) 2019-10-29
ES2584247T3 (es) 2016-09-26
SI1910839T1 (sl) 2016-06-30
CN101278196A (zh) 2008-10-01
JP2012125248A (ja) 2012-07-05
RU2008107318A (ru) 2009-09-10
EP1910839B1 (en) 2016-04-27
WO2007013576A1 (en) 2007-02-01
KR101325194B1 (ko) 2013-11-06
AU2006273192B2 (en) 2011-09-01
CA2616497C (en) 2016-06-07
AU2006273192A1 (en) 2007-02-01
CN101278196B (zh) 2013-05-15
EP1910839A1 (en) 2008-04-16
RU2449020C2 (ru) 2012-04-27
BRPI0613970A2 (pt) 2011-02-22
HUE027330T2 (en) 2016-09-28
US20090214571A1 (en) 2009-08-27
RU2011127868A (ru) 2013-01-20
PL1910839T3 (pl) 2016-11-30
RU2526196C2 (ru) 2014-08-20
CA2616497A1 (en) 2007-02-01
CY1117839T1 (el) 2017-05-17
DK1910839T3 (en) 2016-07-04
JP2009502732A (ja) 2009-01-29
PT1910839T (pt) 2016-07-14

Similar Documents

Publication Publication Date Title
ATE419390T1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
WO2006085684A3 (en) Method of diagnosing bladder cancer
ATE508202T1 (de) Verfahren zur diagnose von brustkrebs
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
EP1904111A4 (en) COMPOSITIONS AND METHODS FOR REDUCING MICRORNA EXPRESSION FOR THE TREATMENT OF NEOPLASIA
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
CA2735578C (en) Method of identifying risk factors for alzheimer's disease comprising tomm40 gene variants
WO2007013665A3 (en) Method of diagnosing small cell lung cancer
FI20050011A7 (fi) Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi
AR057631A1 (es) Composiciones y metodos para incrementar la sensibilidad a insulina
TW200833842A (en) Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
PE20120015A1 (es) Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
WO2008028031A3 (en) Markers and methods for assessing and treating ulcerative colitis and related disorders using a 43 gene panel
BRPI0714563B8 (pt) métodos para detectar a pré-disposição à ou estágio de um câncer em um indivíduo mamífero, para triagem, identificação ou otimização de um medicamento anti-câncer, para modificação de um gene de mamífero in vitro e para avaliação da eficácia de um medicamento anti-câncer ou medicamento candidato
WO2003046578A3 (en) Method for the assessment and prognosis of sarcoidosis
WO2007013575A3 (en) Method for diagnosing and treating renal cell carcinoma
BRPI0613970B8 (pt) composição para o tratamento ou para a prevenção de câncer de cólon compreende uma quantidade farmaceuticamente eficaz de um sirna contra um polinucleotídeo de tom 34
PT1529116E (pt) Métodos para o tratamento da demência com base no genótipo da apo e
WO2007127237A3 (en) Methods of diagnosing and treating migraine
WO2006119775A3 (en) Method for diagnosis and treatment, of a mental disease
TW200643176A (en) ZNFN3A1/breast cancer related gene ZNFN3A1
WO2007013360A3 (en) Pancreatic cancer related gene cst6 and gabrp
WO2012074550A3 (en) Methods to assess treatment outcomes in reward deficiency syndrome (rds) behaviors utilizing expression profiling
Kaut et al. DNA methylation of DLG4 and GJA-1 of human hippocampus and prefrontal cortex in major depression is unchanged in comparison to healthy individuals

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2153 DE 10/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/07/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2732 DE 16-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.